Aprotinin and similar protease inhibitors as drugs against influenza

Antiviral Research

Volumn 92, Issue 1, 2011, Pages 27-36

  Zhirnov, O P ^a   Klenk, H D ^b   Wright, P F ^c,d  

^a D I IVANOVSKY INSTITUTE OF VIROLOGY   (Russian Federation)

^b UNIVERSITY HOSPITAL MARBURG   (Germany)

^c DARTMOUTH MEDICAL SCHOOL   (United States)

^d NONE

Author keywords

Aerosol; Antivirals; Aprotinin; HA cleavage; Influenza; Protease inhibitors

Indexed keywords

APROTININ; CAMOSTAT; HEMAGGLUTININ; LEUPEPTIN; PLACEBO; PROTEINASE INHIBITOR;

DRUG TARGETING; HUMAN; INFLUENZA; INFLUENZA VIRUS; NONHUMAN; PRIORITY JOURNAL; REVIEW; VIRUS REPLICATION;

ANIMALS; APROTININ; HEMAGGLUTININS; HUMANS; INFLUENZA, HUMAN; ORTHOMYXOVIRIDAE; SERINE ENDOPEPTIDASES; SERINE PROTEINASE INHIBITORS; VIRAL PROTEINS;

AVIAN INFLUENZA VIRUS; BOVINAE; ORTHOMYXOVIRIDAE;

EID: 80052847571     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2011.07.014     Document Type: Review

References (129)

1. Akaike T., Molla A., Ando M., Araki S., Maeda H. Molecular mechanism of complex infection by bacteria and virus analyzed by a model using serratial protease and influenza virus in mice. J. Virol. 1989, 63(5):2252-2259.
2. Akaike T., Ando M., Oda T., Doi T., Ijiri S., Araki S., Maeda H. Dependence on O2-generation by xanthine oxidase of pathogenesis of influenza virus infection in mice. J. Clin. Invest. 1990, 85(3):739-745.
3. Akaike T., Noguchi Y., Ijiri S., Setoguchi K., Suga M., Zheng Y.M., Dietzschold B., Maeda H. Pathogenesis of influenza virus-induced pneumonia: involvement of both nitric oxide and oxygen radicals. Proc. Natl. Acad. Sci. USA 1996, 93(6):2448-2453.
4. Amara U., Rittirsch D., Flierl M., Bruckner U., Klos A., Gebhard F., Lambris J.D., Huber-Lang M. Interaction between the coagulation and complement system. Adv. Exp. Med. Biol. 2008, 632:71-79.
5. Asimakopoulos G., Lidington E.A., Mason J., Haskard D.O., Taylor K.M., Landis R.C. Effect of aprotinin on endothelial cell activation. J. Thorac. Cardiovasc. Surg. 2001, 122(1):123-128.
6. Attali C., Durmort C., Vernet T., Di Guilmi A.M. The interaction of Streptococcus pneumoniae with plasmin mediates transmigration across endothelial and epithelial monolayers by intercellular junction cleavage. Infect. Immun. 2008, 76(11):5350-5356.
7. Barnett J.K., Cruse L.W., Proud D. Kinins are generated in nasal secretions during influenza A infections in ferrets. Am. Rev. Respir. Dis. 1990, 142(1):162-166.
8. Beierlein W., Scheule A.M., Antoniadis G., Braun C., Schosser R. An immediate, allergic skin reaction to aprotinin after reexposure to fibrin sealant. Transfusion 2000, 40(3):302-305.
9. Beierlein W., Scheule A.M., Dietrich W., Ziemer G. Forty years of clinical aprotinin use: a review of 124 hypersensitivity reactions. Ann. Thorac. Surg. 2005, 79:741-748.
10. Belser J.A., Lu X., Szretter K.J., Jin X., Aschenbrenner L.M., Lee A., Hawley S., Kim do H., Malakhov M.P., Yu M., Fang F., Katz J.M. DAS181, a novel sialidase fusion protein, protects mice from lethal avian influenza H5N1 virus infection. J. Infect. Dis. 2007, 196(10):1493-1499.
11. Beppu Y., Imamura Y., Tashiro M., Towatari T., Ariga H., Kido H. Human mucus protease inhibitor in airway fluid is a potential defensive compound against infection with influenza A and Sendai virus. J. Biochem. 1997, 121:309-316.
12. Bertram S., Glowacka I., Blazejewska P., Soilleux E., Allen P., Danisch S., Steffen I., Choi S.Y., Park Y., Schneider H., Schughart K., Pöhlmann S. TMPRSS2 and TMPRSS4 facilitate trypsin-independent spread of influenza virus in Caco-2 cells. J. Virol. 2010, 84(19):10016-10025.
13. Beigel J.H., Farrar J., Han A.M., Hayden F.G., Hyer R., de Jong M.D., Lochindarat S., Nguyen T.K., Nguyen T.H., Tran T.H., Nicoll A., Touch S., Yuen K.Y. Writing Committee of the World Health Organization (WHO) Consultation on Human Influenza A/H5. Avian influenza A (H5N1) infection in humans. N. Engl. J. Med. 2005, 353(13):1374-1385.
14. Böttcher E., Matrosovich T., Beyerle M., Klenk H.D., Garten W., Matrosovich M. Proteolytic activation of influenza viruses by serine proteases TMPRSS2 and HAT from human airway epithelium. J. Virol. 2006, 80(19):9896-9898.
15. Böttcher-Friebertshäuser E., Freuer C., Sielaff F., Schmidt S., Eickmann M., Uhlendorff J., Steinmetzer T., Klenk H.D., Garten W. Cleavage of influenza virus hemagglutinin by airway proteases TMPRSS2 and HAT differs in subcellular localization and susceptibility to protease inhibitors. J. Virol. 2010, 84(11):5605-5614.
16. Boycott R., Klenk H.D., Ohuchi M. Cell tropism of influenza virus mediated by hemagglutinin activation at the stage of virus entry. Virology 1994, 203(2):313-319.
17. Bruda N.L., Hurlbert B.J., Hill G.E. Aprotinin reduces nitric oxide production in vitro and in vivo in a dose-dependent manner. Clin. Sci. 1998, 94(5):505-509.
18. Busuttil R.W. A comparison of antifibrinolytic agents used in hemostatic fibrin sealants. J. Am. Coll. Surg. 2003, 197(6):1021-1028.
19. Callan R.J., Hartmann F.A., West S.E., Hinshaw V.S. Cleavage of influenza A virus H1 hemagglutinin by swine respiratory bacterial proteases. J. Virol. 1997, 71(10):7579-7585.
20. CDC. Antiviral Drug-Resistance among Influenza Viruses. Guidance on the Use of Influenza Antiviral Agents During the 2010-2011 Influenza Season. Atlanta, GA: US Department of Health and Human Services. CDC; 2011. http://www.cdc.gov/flu/professionals/antivirals/antiviral-drug-resistance.htm.
21. Chaipan C., Kobasa D., Bertram S., Glowacka I., Steffen I., Tsegaye T.S., Takeda M., Bugge T.H., Kim S., Park Y., Marzi A., Pöhlmann S. Proteolytic activation of the 1918 influenza virus hemagglutinin. J. Virol. 2009, 83(7):3200-3211.
22. Chen J., Lee K.H., Steinhauer D.A., Stevens D.J., Skehel J.J., Wiley D.C. Structure of the hemagglutinin precursor cleavage site, a determinant of influenza pathogenicity and the origin of the labile conformation. Cell 1998, 95:409-417.
23. Coote K., Atherton-Watson H.C., Sugar R., Young A., MacKenzie-Beevor A., Gosling M., Bhalay G., Bloomfield G., Dunstan A., Bridges R.J., Sabater J.R., Abraham W.M., Tully D., Pacoma R., Schumacher A., Harris J., Danahay H. Camostat attenuates airway epithelial sodium channel function in vivo through the inhibition of a channel-activating protease. J. Pharmacol. Exp. Ther. 2009, 329(2):764-774.
24. Eriksson B., Helgstrand E., Johansson N.G., Larsson A., Misiorny A., Norén J.O., Philipson L., Stenberg K., Stening G., Stridh S., Oberg B. Inhibition of influenza virus ribonucleic acid polymerase by ribavirin triphosphate. Antimicrob. Agents Chemother. 1977, 11(6):946-951.
25. Fergusson D.A., Hébert P.C., Mazer C.D., Fremes S., MacAdams C., Murkin J.M., Teoh K., Duke P.C., Arellano R., Blajchman M.A., Bussières J.S., Côté D., Karski J., Martineau R., Robblee J.A., Rodger M., Wells G., Clinch J., Pretorius R. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N. Engl. J. Med. 2008, 358(22):2319-2331. BART Investigators.
26. Fritz H., Wunderer G. Biochemistry and application of aprotinin, the Kallikrein inhibitor from bovine organs. Arzneim.-Forsch./Drug Res. 1983, 33(1):479-494.
27. Fujimoto S., Kobayashi M., Uemura O., Iwasa M., Ando T., Katoh T., Nakamura C., Maki N., Togari H., Wada Y. PCR on cerebrospinal fluid to show influenza-associated acute encephalopathy or encephalitis. Lancet 1998, 352(9131):873-875.
28. Furuta Y., Takahashi K., Kuno-Maekawa M., Sangawa H., Uehara S., Kozaki K., Nomura N., Egawa H., Shiraki K. Mechanism of action of T-705 against influenza virus. Antimicrob. Agents Chemother. 2005, 49(3):981-986.
29. Ganderton D., Lewis D., Davies R., Meakin B., Brambilla G., Church T. Modulite: a means of designing the aerosols generated by pressurized metered dose inhalers. Respir. Med. 2002, 96(Suppl. D):S3-S8.
30. Garozzo A., Tempera G., Ungheri D., Timpanaro R., Castro A. N-acetylcysteine synergizes with oseltamivir in protecting mice from lethal influenza infection. Int. J. Immunopathol. Pharmacol. 2007, 20:349-354.
31. Garten W., Klenk H.D., 2009. Cleavage activation of the influenza virus hemagglutinin and its role in pathogenesis. In: Klenk H.D., Matrosovich M.N., Stech J. (Eds.), Avian Influenza. Monogr.Virol. Basel, Karger, 2008, vol. 27, 156-167.
32. Ghanem A., Mayer D., Chase G., Tegge W., Frank R., Kochs G., García-Sastre A., Schwemmle M. Peptide-mediated interference with influenza A virus polymerase. J. Virol. 2007, 81(14):7801-7804.
33. Ghezzi P., Ungheri D. Synergistic combination of N-acetylcysteine and ribavirin to protect from lethal influenza viral infection in a mouse model. Int. J. Immunopathol. Pharmacol. 2004, 17:99-102.
34. Gilliland H.E., Armstrong M.A., Uprichard S., Clarke G., McMurray T.J. The effect of aprotinin on interleukin-8 concentration and leukocyte adhesion molecule expression in an isolated cardiopulmonary bypass system. Anaesthesia 1999, 54(5):427-433.
35. Goto H., Kawaoka Y. A novel mechanism for the acquisition of virulence by a human influenza A virus. Proc. Natl. Acad. Sci. USA 1998, 95(17):10224-10228.
36. Goto H., Wells K., Takada A., Kawaoka Y. Plasminogen-binding activity of neuraminidase determines the pathogenicity of influenza A virus. J. Virol. 2001, 75(19):9297-9301.
37. Hayashi T., Hotta H., Itoh M., Homma M. Protection of mice by a protease inhibitor, aprotinin, against lethal Sendai virus pneumonia. J. Gen. Virol. 1991, 72(Pt 4):979-982.
38. Harig F., Feyrer R., Mahmoud F.O., Blum U., von der Emde J. Reducing the post-pump syndrome by using heparin-coated circuits, steroids, or aprotinin. Thorac. Cardiovasc. Surg. 1999, 47(2):111-118.
39. Helland R., Otlewski J., Sundheim O., Dadlez M., Smalås A.O. The crystal structures of the complexes between bovine beta-trypsin and ten P1 variants of BPTI. J. Mol. Biol. 1999, 287(5):923-942.
40. Heimburger N. Proteinase inhibitors of human plasma - their properties and control functions. Proteainases and Biological Control 1975, 367-386. Cold Spring Harbour Laboratory, Cold Spring Harbour, NY. E. Reich, D.B. Rifkin, E. Shaw (Eds.).
41. Hennet T., Peterhans E., Stocker R. Alterations in antioxidant defences in lung and liver of mice infected with influenza A virus. J. Gen. Virol. 1992, 73(Pt 1):39-46.
42. Hill G.E., Robbins R.A. Aprotinin but not tranexamic acid inhibits cytokine-induced inducible nitric oxide synthase expression. Anesth. Analg. 1997, 84(6):1198-1202.
43. Hogue C.W., London M.J. Aprotinin use during cardiac surgery: a new or continuing controversy?. Anesth. Analg. 2006, 103(5):1067-1070.
44. Hooper J.D., Clements J.A., Quigley J.P., Antalis T.M. Type II transmembrane serine proteases. Insights into an emerging class of cell surface proteolytic enzymes. J. Biol. Chem. 2001, 276(2):857-860.
45. Hosoya M., Matsuyama S., Baba M., Suzuki H., Shigeta S. Effects of protease inhibitors on replication of various myxoviruses. Antimicrob. Agents Chemother. 1992, 36(7):1432-1436.
46. Huber-Lang M., Sarma J.V., Zetoune F.S., Rittirsch D., Neff T.A., McGuire S.R., Lambris J.D., Warner R.L., Flierl M.A., Hoesel L.M., Gebhard F., Younger J.G., Drouin S.M., Wetsel R.A., Ward P.A. Generation of C5a in the absence of C3: a new complement activation pathway. Nat. Med. 2006, 12(6):682-687.
47. Kaller H., Patzschke K., Wegner L.A., Horster F.A. Pharmacokinetic observations following intravenous administration of radioactive labeled aprotinin in volunteers. Eur. J. Drug Metabol. Pharmacokinet. 1978, 3(2):79-85.
48. Kao R.Y., Yang D., Lau L.S., Tsui W.H., Hu L., Dai J., Chan M.P., Chan C.M., Wang P., Zheng B.J., Sun J., Huang J.D., Madar J., Chen G., Chen H., Guan Y., Yuen K.Y. Identification of influenza A nucleoprotein as an antiviral target. Nat. Biotechnol. 2010, 28(6):600-605.
49. Kassell B. Bovine trypsin-kallikrein inhibitor (Kunitz inhibitor, basic pancreatic trypsin inhibitor, polyvalent inhibitor from bovine organs). Meth. Enzym. 1970, 19:844-852.
50. Kawaoka Y., Webster R.G. Interplay between carbohydrate in the stalk and the length of the connecting peptide determines the cleavability of influenza virus hemagglutinin. J. Virol. 1989, 63(8):3296-3300.
51. Khan T.A., Bianchi C., Voisine P., Sandmeyer J., Feng J., Sellke F.W. Aprotinin inhibits protease-dependent platelet aggregation and thrombosis. Ann. Thorac. Surg. 2005, 79(5):1545-1550.
52. Khatchikian D., Orlich M., Rott R. Increased viral pathogenicity after insertion of a 28S ribosomal RNA sequence into the haemagglutinin gene of an influenza virus. Nature 1989, 340(6229):156-157.
53. Kido H., Yokogoshi Y., Sakai K., Tashiro N., Kishino Y., Fukutomi A., Katanuma N. Isolation and characterization of a novel trypsin-like protease found in rat bronchiolar epithelial Clara cells. Possible activator of the viral fusion glycoprotein. J. Biol. Chem. 1992, 267:13573-13579.
54. Kido H., Sakai K., Kishino Y., Tashiro M. Pulmonary surfactant is a potential endogenous inhibitor of proteolytic activation of Sendai virus and influenza A virus. FEBS Lett. 1993, 322:115-119.
55. Kido H., Niwa Y., Beppu Y., Towatari T. Cellular proteases involved in the pathogenicity of enveloped animal viruses, human immunodeficiency virus, influenza virus A and Sendai virus. Advan. Enzyme. Regul. 1996, 36:325-347.
56. Klenk H.D., Rott R., Orlich M., Blodorn J. Activation of influenza A viruses by trypsin treatment. Virology 1975, 68:426-439.
57. Krowarsch D., Zakrzewska M., Smalas A.O., Otlewski J. Structure-function relationships in serine protease-bovine pancreatic trypsin inhibitor interaction. Protein Pept. Lett. 2005, 12(5):403-407.
58. Lazarowitz S.G., Goldberg A.R., Choppin P.W. Proteolytic cleavage by plasmin of a HA polypeptide of influenza virus: host cell activation of serum plasminogen. Virology 1973, 56:172-180.
59. Lazarowitz S.G., Choppin P.W. Enhancement of the infectivity of influenza A and B viruses by proteolytic cleavage of the hemagglutinin polypeptide. Virology 1975, 68:440-454.
60. LeBouder F., Lina B., Rimmelzwaan G.F., Riteau B. Plasminogen promotes influenza A virus replication through an annexin 2-dependent pathway in the absence of neuraminidase. J. Gen. Virol. 2010, 91(Pt 11):2753-2761.
61. Levy J.H., Adkinson N.F. Anaphylaxis during cardiac surgery: implications for clinicians. Anesth. Analg. 2008, 106:392-403.
62. Liao T.L., Wu C.Y., Su W.C., Jeng K.S., Lai M.M. Ubiquitination and deubiquitination of NP protein regulates influenza A virus RNA replication. EMBO J. 2010, 29(22):3879-3890.
63. Ludwig S. Targeting cell signaling pathways for fight the flu: towards a paradigm change in anti-influenza therapy. J. Antimicrob. Chemother. 2009, 61:1-4.
64. Lyon J.B., Remigio C., Milligan T., Deline C. Acute necrotizing encephalopathy in a child with H1N1 influenza infection. Pediatr. Radiol. 2010, 40(2):200-205.
65. Malakhov M.P., Aschenbrenner L.M., Smee D.F., Wandersee M.K., Sidwell R.W., Gubareva L.V., Mishin V.P., Hayden F.G., Kim D.H., Ing A., Campbell E.R., Yu M., Fang F. Sialidase fusion protein as a novel broad-spectrum inhibitor of influenza virus infection. Antimicrob. Agents. Chemother. 2006, 50(4):1470-1479.
66. Mangano D.T., Tudor I.C., Dietzel C. The risk associated with aprotinin in cardiac surgery. N. Engl. J. Med. 2006, 354(4):353-365.
67. McEvoy M.D., Reeves S.T., Reves J.G., Spinale F.G. Aprotinin in cardiac surgery: a review of conventional and novel mechanisms of action. Anesth. Analg. 2007, 105(4):949-962.
68. Meta A., Nakatake H., Imamura T., Nozaki C., Sugimura K. High-yield production and characterization of biologically active recombinant aprotinin expressed in Saccharomyces cerevisiae. Protein Expr. Purif. 2009, 66(1):22-27.
69. Moscona A. Oseltamivir resistance - disabling our influenza defenses. N. Engl. J. Med. 2005, 353(25):2633-2636.
70. Moscona A. Global transmission of oseltamivir-resistant influenza. N. Engl. J. Med. 2009, 360(10):953-956.
71. Murakami M., Towatari T., Ohuchi M., Shiota M., Akao M., Okumura Y., Parry M.A.A., Kido H. Mini-plasmin found in the epithelial cells of bronchioles triggers infection by broad-spectrum influenza A viruses and Sendai virus. Eur. J. Biochem. 2001, 268:2847-2855.
72. Netzel-Arnett S., Hooper J.D., Szabo R., Madison E.L., Quigley J.P., Bugge T.H., Antalis T.M. Membrane anchored serine proteases: a rapidly expanding group of cell surface proteolytic enzymes with potential roles in cancer. Cancer Metastasis Rev. 2003, 22(2-3):237-258.
73. Ohuchi M., Orlich M., Ohuchi R., Simpson B.E., Garten W., Klenk H.D., Rott R. Mutations at the cleavage site of the hemagglutinin after the pathogenicity of influenza virus A/chick/Penn/83 (H5N2). Virology 1989, 168(2):274-280.
74. Ohuchi R., Ohuchi M., Garten W., Klenk H.D. Human influenza virus hemagglutinin with high sensitivity to proteolytic activation. J. Virol. 1991, 65(7):3530-3537.
75. Ollier L., Caramella A., Giordanengo V., Lefebvre J.C. High permissivity of human HepG2 hepatoma cells for influenza viruses. J. Clin. Microbiol. 2004, 42(12):5861-5865.
76. Okumura Y., Takahashi E., Yano M., Ohuchi M., Daidoji T., Nakaya T., Böttcher E., Garten W., Klenk H.D., Kido H. Novel type II transmembrane serine proteases, MSPL and TMPRSS13, proteolytically activate membrane fusion activity of the hemagglutinin of highly pathogenic avian influenza viruses and induce their multicycle replication. J. Virol. 2010, 84(10):5089-5096.
77. Ovcharenko A.V., Zhirnov O.P. Aprotinin aerosol treatment of influenza and paramyxovirus bronchopneumonia of mice. Antiviral Res. 1994, 23:107-118.
78. Pan H.Y., Yano M., Kido H. Effects of inhibitors of Toll-like receptors, protease-activated receptor-2 signalings and trypsin on influenza A virus replication and upregulation of cellular factors in cardiomyocytes. J. Med. Invest. 2011, 58(1-2):19-28.
79. Pan H.Y., Yamada H., Chida J., Wang S., Yano M., Yao M., Zhu J., Kido H. Up-regulation of ectopic trypsin in the myocardium by influenza A virus infection triggers acute myocarditis. Cardiovasc. Res. 2011, 89(3):595-603.
80. Pasquali S.K., Hall M., Li J.S., Peterson E.D., Jaggers J., Lodge A.J., Jacobs J.P., Jacobs M.L., Shah S.S. Safety of aprotinin in congenital heart operations: results from a large multicenter database. Ann. Thorac. Surg. 2010, 90(1):14-21.
81. Passero C.J., Hughey R.P., Kleyman T.R. New role for plasmin in sodium homeostasis. Curr. Opin. Nephrol. Hypertens. 2010, 19(1):13-19.
82. Patlolla R.R., Chougule M., Patel A.R., Jackson T., Tata P.N.V., Singh M. Formulation, characterization and pulmonary deposition of nebulized Celecoxib encapsulated nanostructured lipid carriers. J. Control Release 2011, 144(2):233-241.
83. Pinto L.H., Lamb R.A. The M2 proton channels of influenza A and B viruses. J. Biol. Chem. 2006, 281(14):8997-9000.
84. Planès C., Caughey G.H. Regulation of the epithelial Na+ channel by peptidases. Curr. Top Dev. Biol. 2007, 78:23-46.
85. Poullis M., Manning R., Laffan M., Haskard D.O., Taylor K.M., Landis R.C. The antithrombotic effect of aprotinin: actions mediated via the protease activated receptor 1. J. Thorac. Cardiovasc. Surg. 2000, 120(2):370-378.
86. Pruefer D., Makowski J., Dahm M., Guth S., Oelert H., Darius H., Buerke M. Aprotinin inhibits leukocyte-endothelial cell interactions after hemorrhage and reperfusion. Ann. Thorac. Surg. 2003, 75(1):210-215.
87. Ray M.J., Marsh N.A. Aprotinin reduces blood loss after cardiopulmonary bypass by direct inhibition of plasmin. Thromb. Haemost. 1997, 78(3):1021-1026.
88. Rasche B., Marcic I., Ulmer W.T. Effect of the protease inhibitor aprotinin on pulmonary function and on the inhibitory activity of sputum in patients with chronic obstructive bronchitis. Arzneimittelforschung 1975, 25(1):110-116.
89. Reichert R., Hochstrasser K., Werle E. Protease inhibitor levels in human nasal mucus under physiological and physiopathological conditions. Klin Wochenschr 1971, 49(22):1234-1236.
90. Russell R.J., Kerry P.S., Stevens D.J., Steinhauer D.A., Martin S.R., Gamblin S.J., Skehel J.J. Structure of influenza hemagglutinin in complex with an inhibitor of membrane fusion. Proc. Natl. Acad. Sci. USA 2008, 105(46):17736-17741.
91. Sarma V.J., Huber-Lang M., Ward P.A. Complement in lung disease. Autoimmunity 2006, 39(5):387-394.
92. Sato M., Yoshida S., Iida K., Tomozawa T., Kido H., Yamashita M. A novel influenza A virus activating enzyme from porcine lung: purification and characterization. Biol. Chem. 2003, 384(2):219-227.
93. Scheiblauer H., Reinacher M., Tashiro M., Rott R. Interactions between bacteria and influenza A virus in the development of influenza pneumonia. J. Infect. Dis. 1992, 166(4):783-791.
94. Seta T., Noguchi Y., Shimada T., Shikata S., Fukui T. Treatment of acute pancreatitis with protease inhibitors: a meta-analysis. Eur. J. Gastroenterol. Hepatol. 2004, 16(12):1287-1293.
95. Shaw A.D., Stafford-Smith M., White W.D., Phillips-Bute B., Swaminathan M., Milano C., Welsby I.J., Aronson S., Mathew J.P., Peterson E.D., Newman M.F. The effect of aprotinin on outcome after coronary-artery bypass grafting. N. Engl. J. Med. 2008, 358(8):784-793.
96. Smith M., Kocher H.M., Hunt B.J. Aprotinin in severe acute pancreatitis. Int. J. Clin. Pract. 2010, 64(1):84-92.
97. Sun Z., Lu W., Jiang A., Chen J., Tang F., Liu J.N. Expression, purification and characterization of aprotinin and a human analogue of aprotinin. Protein Expr. Purif. 2009, 65(2):238-243.
98. Sun X., Tse L.V., Ferguson A.D., Whittaker G.R. Modifications to the hemagglutinin cleavage site control the virulence of a neurotropic H1N1 influenza virus. J. Virol. 2010, 84(17):8683-8690.
99. Tashiro M., Klenk H.D., Rott R. Inhibitory effect of a protease inhibitor, leupeptin, on the evelopment of influenza pneumonia, mediated by concomitant bacteria. J. Gen. Virol. 1987, 68(Pt 7):2039-2041.
100. Tashiro M., Ciborowski P., Reinacher M., Pulverer G., Klenk H.D., Rott R. Synergistic role of staphylococcal proteases in the induction of influenza virus pathogenicity. Virology 1987, 157(2):421-430.
101. Tashiro M., Ciborowski P., Klenk H.D., Pulverer G., Rott R. Role of Staphylococcus protease in the development of influenza pneumonia. Nature 1987, 325(6104):536-537.
102. Thorlund K., Awad T., Boivin G., Thabane L. Systematic review of influenza resistance to the neuraminidase inhibitors. BMC Infect. Dis. 2011, 11(1):134. (Epub ahead of print; PubMed PMID: 21592407).
103. Towatari T., Ide M., Ohba K., Chiba Y., Murakami M., Shiota M., Kawachi M., Yamada H., Kido H. Identification of ectopic anionic trypsin I in rat lungs potentiating pneumotropic virus infectivity and increased enzyme level after virus infection. Eur. J. Biochem. 2002, 269(10):2613-2621.
104. Trautschold I., Werle E., Zickgraf-Rudel G. Trasylol. Biochem. Pharmacol. 1967, 16:59-72.
105. Vusicevic Z., Suskevic T. Acute respiratory distress syndrome after aprotinin infusion. Ann. Pharmacother. 1997, 31:429-432.
106. Wachtfogel Y.T., Kucich U., Hack C.E., Gluszko P., Niewiarowski S., Colman R.W., Edmunds L.H. Aprotinin inhibits the contact, neutrophil, and platelet activation systems during simulated extracorporeal perfusion. J. Thorac. Cardiovasc. Surg. 1993, 106(1):1-9.
107. Wachtfogel Y.T., Hack C.E., Nuijens J.H., Kettner C., Reilly T.M., Knabb R.M., Bischoff R., Tschesche H., Wenzel H., Kucich U., et al. Selective kallikrein inhibitors alter human neutrophil elastase release during extracorporeal circulation. Am. J. Physiol. 1995, 268(3 Pt 2):H1352-H1357.
108. Walkiewicz M.P., Basu D., Jablonski J.J., Geysen H.M., Engel D.A. Novel inhibitor of influenza non-structural protein 1 blocks multi-cycle replication in an RNase L-dependent manner. J. Gen. Virol. 2011, 92(Pt 1):60-70.
109. Werle E., Trautschold I., Haendle H., Fritz H. Physiologic, pharmacologic, and clinical aspects of proteinase inhibitors. Ann. NY Acad. Sci. 1968, 146(2):464-478.
110. Wilson I.A., Skehel J.J., Wiley D.C. Structure of the haemagglutinin membrane glycoprotein of influenza virus at 3 A resolution. Nature 1981, 289(5796):366-373.
111. Wu Y., Zhang G., Li Y., Jin Y., Dale R., Sun L.Q., Wang M. Inhibition of highly pathogenic avian H5N1 influenza virus replication by RNA oligonucleotides targeting NS1 gene. Biochem. Biophys. Res. Commun. 2008, 365(2):369-374.
112. Yayama K., Kunimatsu N., Teranishi Y., Takano M., Okamoto H. Tissue kallikrein is synthesized and secreted by human vascular endothelial cells. Biochim. Biophys. Acta. 2003, 1593(2-3):231-238.
113. Zhang H. Concerns of using sialidase fusion protein as an experimental drug to combat seasonal, pandemic influenza. J. Antimicrob. Chemother. 2008, 62(2):219-223.
114. Zheng B.J., Chan K.W., Lin Y.P., Zhao G.Y., Chan C., Zhang H.J., Chen H.L., Wong S.S., Lau S.K., Woo P.C., Chan K.H., Jin D.Y., Yuen K.Y. Delayed antiviral plus immunomodulator treatment still reduces mortality in mice infected by high inoculum of influenza A/H5N1 virus. Proc. Natl. Acad. Sci. USA 2008, 105:8091-8096.
115. Zhirnov O.P., Ovcharenko A.V., Bukrinskaya A.G. Proteolytic activation of influenza WSN virus in cultured cells is performed by homologous plasma enzymes. J. Gen. Virol. 1982, 63:469-474.
116. Zhirnov O.P. Proteolytic activation of myxoviruses and a new strategy in the treatment of viral diseases. Voprosi Virusol./Progress in Soviet Virol. 1983, 4:9-21.
117. Zhirnov O.P., Ovcharenko A.V., Bukrinskaya A.G. Protective effect of protease inhibitors in influenza virus infected animals. Arch. Virol. 1982, 73(3-4):263-272.
118. Zhirnov O.P., Ovcharenko A.V., Bukrinskaya A.G. A modified plaque assay method for accurate analysis of infectivity of influenza viruses with uncleaved hemagglutinin. Arch. Virol. 1982, 71(2):177-183.
119. Zhirnov O.P., Ovcharenko A.V., Bukrinskaya A.G. Suppression of influenza virus replication in infected mice by protease inhibitors. J. Gen. Virol. 1984, 65:191-196.
120. Zhirnov O.P., Ovcharenko A.V., Bukrinskaya A.G. Myxovirus replication in chicken embryos can be suppressed by aprotinin due to the blockage of viral glycoprotein cleavage. J. Gen. Virol. 1985, 66:1633-1638.
121. Zhirnov O.P. High protection of animals lethally infected with influenza virus by aprotinin-rimantadine combination. J. Med. Virol. 1987, 21:161-167.
122. Zhirnov O.P., Ovcharenko A.V., Golyando P.B., Svinogeeva T.P., Dolgova A.V., Nikitin A.V. The antiviral aerosol of aprotinin. 1. General effect on the body after inhalation administration. Antibiot. Chemother. 1994, 5:25-32.
123. Zhirnov O.P., Ovcharenko A.V., Golyando P.B., Svinogeeva T.P., Dolgova A.V., Nikitin A.V. The antiviral aerosol of aprotinin. 2. The lack of local irritating and allergenic effects. Antibi. Chemother. 1994, 9(10):53-57.
124. Zhirnov O.P. Solubilization of matrix protein M1/M from virions occurs at different pH for orthomyxo- and paramyxoviruses. Virology 1990, 176(1):274-279.
125. Zhirnov O.P., Kirzhner L.S., Ovcharenko A.V., Malyshev N.A. Aerosolized aprotinin is an effective drug against viral respiratory illness. Antiinfect. Drug Chemother. 1996, 14:209-216.
126. Zhirnov O.P., Kirzhner L.S., Ovcharenko A.V., Malyshev N.A. Clinical effectiveness of aprotinin aerosol in influenza and parainfluenza. Vestn. Ross Akad. Med. Nauk. 1996, 5:26-31.
127. Zhirnov O.P., Ikizler M.R., Wright P. Cleavage of influenza A virus hemagglutinin in human respiratory epithelium is cell-associated and sensitive to exogenous antiproteases. J. Virol. 2002, 76:8682-8689.
128. Zhirnov O.P., Klenk H.D. Human influenza viruses are proteolytically activated and do not induce apoptosis in CACO-2 cells. Virology 2003, 313:198-2002.
129. Zhirnov O.P., Matrosovich T.Y., Matrosovich M.N., Klenk H.D. Aprotinin, a protease inhibitor, suppresses proteolytic activation of pandemic H1N1v influenza virus. Antiviral Chem. Chemother. 2011, 21:169-174.